spot_img
Sunday, July 3, 2022
More
    HomeHealthPfizer to pay Beam $300M in gene editing deal, upping its mRNA...

    Pfizer to pay Beam $300M in gene editing deal, upping its mRNA ambitions

    -



    Pfizer is making a significant push to leverage mRNA know-how, on which its Covid-19 vaccine is predicated, to develop new vaccines and coverings.

    The drug big stated Monday it can pay Beam Therapeutics, a Cambridge, Mass., startup based by Harvard researcher David Liu, $300 million to spend 4 years growing remedies for 3 undisclosed uncommon genetic illnesses affecting the liver, the muscle tissue, and the central nervous system.

    Unlock this text by subscribing to STAT+ and revel in your first 30 days free!

    GET STARTED





    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,380FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts